Fractyl Health Outlines Path to Reduced Cash Burn Amid Revita Regulatory Progress
Fractyl Health (GUTS) management has detailed a strategic plan to reduce quarterly operating cash expenditures to approximately $8 million by the end of Q2 2027. This cost-cutting measure coincides with the company's progress toward a de novo regulatory submission for its Revita product. CEO Harith Rajagopalan highlighted a significant market opportunity driven by shifting weight-loss medication trends, noting that approximately one million patients are discontinuing GLP-1 treatments each month. The company is positioning Revita as a one-time outpatient alternative to address the needs of these transitioning patients.
Tickers: $GUTS
Topics: earnings call GLP-1 discontinuation medical devices outpatient procedures